Literature DB >> 16732329

Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells.

A A Wani1, N Sharma, Y S Shouche, S A Bapat.   

Abstract

Analyses of genome orthologs in cancer on the background of tumor heterogeneity, coupled with the recent identification that the tumor propagating capacity resides within a very small fraction of cells (the tumor stem cells-TSCs), has not been achieved. Here, we describe a strategy to explore genetic drift in the mitochondrial genome accompanying varying stem cell dynamics in epithelial ovarian cancer. A major and novel outcome is the identification of a specific mutant mitochondrial DNA profile associated with the TSC lineage that is drastically different from the germ line profile. This profile, however, is often camouflaged in the primary tumor, and sometimes may not be detected even after metastases, questioning the validity of whole tumor profiling towards determining individual prognosis. Continuing mutagenesis in subsets with a mutant mitochondrial genome could result in transformation through a cooperative effect with nuclear genes - a representative example in our study is a tumor suppressor gene viz. cAMP responsive element binding binding protein. This specific profile could be a critical predisposing step undertaken by a normal stem cell to overcome a tightly regulated mutation rate and DNA repair in its evolution towards tumorigenesis. Our findings suggest that varying stem cell dynamics and mutagenesis define TSC progression that may clinically translate into increasing tumor aggression with serious implications for prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732329     DOI: 10.1038/sj.onc.1209649

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  Minireview: stem cell contribution to ovarian development, function, and disease.

Authors:  Jonathan L Tilly; Bo R Rueda
Journal:  Endocrinology       Date:  2008-06-12       Impact factor: 4.736

2.  Ovarian tumor-initiating cells display a flexible metabolism.

Authors:  Angela S Anderson; Paul C Roberts; Madlyn I Frisard; Matthew W Hulver; Eva M Schmelz
Journal:  Exp Cell Res       Date:  2014-08-27       Impact factor: 3.905

3.  Spectrum of CREBBP mutations in Indian patients with Rubinstein-Taybi syndrome.

Authors:  Neeti Sharma; Avinash M Mali; Sharmila A Bapat
Journal:  J Biosci       Date:  2010-06       Impact factor: 1.826

4.  Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells.

Authors:  Jocelyn M Stewart; Patricia A Shaw; Craig Gedye; Marcus Q Bernardini; Benjamin G Neel; Laurie E Ailles
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-30       Impact factor: 11.205

Review 5.  Ovarian cancer stem cells: elusive targets for chemotherapy.

Authors:  Achuta Kumar Guddati
Journal:  Med Oncol       Date:  2012-05-26       Impact factor: 3.064

6.  Epithelial ovarian cancer stem cells-a review.

Authors:  Yueyin Pan; Xudong Huang
Journal:  Int J Clin Exp Med       Date:  2008-06-30

7.  A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.

Authors:  R R Naik; A K Singh; A M Mali; M F Khirade; S A Bapat
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

Authors:  Federica Barbieri; Adriana Bajetto; Tullio Florio
Journal:  J Oncol       Date:  2009-12-14       Impact factor: 4.375

9.  γ-Secretase Inhibitor, DAPT Inhibits Self-renewal and Stemness Maintenance of Ovarian Cancer Stem-like Cells In Vitro.

Authors:  Li-Yu Jiang; Xiao-Lei Zhang; Ping Du; Jian-Hua Zheng
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

Review 10.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.